Möchten Sie immer auf dem neuesten Stand bleiben?

Austin, TX, USA, June 25, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Therapeutic Apheresis Market Size, Trends and Insights By Product Type (Apheresis...

Growing role of machine learning, deep learning and predictive analytics in addressing clinical, operational and economic challenges in kidney care.

Partnership strengthens Istios Health’s network while expanding access to nephrology expertise and cutting-edge research for hospitals and patients.

EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced...

EMPAVELIMD (pegcétacoplan) est le premier traitement autorisé dans le traitement des patients adultes et pédiatriques de 12 ans et plus atteints de glomérulopathie à dépôts de C3 (GC3) ou de...

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia.

Istios Health announced a partnership with Penn Highlands Healthcare to deliver comprehensive virtual nephrology care across its hospital system.

Istios Health Expands Into Nephrology With Three Practice Partnerships in the Northeast

The MHRA (Medicines and Healthcare products Regulatory Agency) granted UK Marketing Authorisation for XOANACYL via the International Recognition Procedure (Route B) recognising its prior EU approval...

Eleva is advancing CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of SAD evaluation in healthy volunteers